Download PDF: Review of the Pharmacoeconomic Research on Gemcitabine in the Treatment of Advanced Non-Small Cell Lung Cancer
Humira: The First $20 Billion Drug
The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Read More
ASH 2022: From Our Partners
Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.
ASH 2022: Health Equity
ASH 2022: COVID-19
ASH 2022: Quality of Care & Cost Savings
ASH 2022: Rare Diseases & Blood Disorders